How did Lilly grow Q3 2026 revenue while realised prices fell?
On October 29, 2026, Eli Lilly reported Q3 2026 revenue of US$24.40 billion, up 39% year over year, as worldwide volume grew 53% while realised prices fell 15%. Drugnews’s November 2, 2026 analysis attributes the reported growth mainly to the volume expansion around Mounjaro and Zepbound, both tirzepatide brands.
| Measure | Reported result | Basis |
|---|---|---|
| Revenue | US$24.40 billion | Reported quarterly revenue |
| Revenue growth | 39% | Year over year |
| Volume growth | 53% | Worldwide |
| Realised price decline | 15% | Worldwide |
The reported growth components should not be treated as a simple multiplication of aggregate price and volume percentages.